Navigation Links
Francisella tularensis: Stopping a biological weapon

Scientists hope a vaccine is on the horizon for tularemia, a fatal disease caused by the pathogen Francisella tularensis, an organism of concern as a potential biological warfare agent. Until recently we knew very little about this bacterium. However, according to the August issue of the Journal of Medical Microbiology, research on the bacterium has been reinvigorated and rapid progress has been made in understanding how it causes disease.

Infection with F. tularensis can result in a variety of symptoms, depending on the route of infection. For example, infection via an insect bite can lead to a swollen ulcer or fever, chills, malaise, headaches and a sore throat. When infection occurs by eating contaminated food, symptoms can range from mild diarrhoea to an acute fatal disease. If inhaled, F. tularensis infections can have a 30% mortality rate if left untreated.

"Only very few bacteria are needed to cause serious disease," said Prof Petra Oyston from Dstl, Porton Down. "Because of this and the fact that tularemia can be contracted by inhalation, Francisella tularensis has been designated a potential biological weapon. Since the events of September 2001 and the subsequent anthrax attacks on the USA, concern about the potential misuse of dangerous pathogens including F. tularensis has increased. As a result, more funding has been made available for research on these organisms and has accelerated progress on developing medical countermeasures."

Tularemia circulates in rodents and animals like rabbits and hares. Outbreaks in humans often happen at the same time as outbreaks in these animals. The disease is probably transmitted by insects like mosquitoes, ticks and deer flies. People can also become infected by contact with contaminated food or water and by breathing in particles containing the bacteria. Farmers, hunters, walkers and forest workers are most at risk of contracting tularemia.

There is currently no vaccine against tularemia. Because there are few natural cases of tularemia, money was not spent on the development of a vaccine. However, various nations developed F. tularensis as a biological weapon, including the reported production of antibiotic-resistant strains, so research into its pathogenesis has become a biodefence issue.

"Progress is being made," said Prof. Oyston. "Since the genome of F. tularensis was sequenced, researchers have taken great strides in understanding the molecular basis for its pathogenesis. This is essential information for developing a vaccine and getting it licensed."

We are still unsure about the function of most F. tularensis genes. "Recently genes needed by F. tularensis for growth and survival have been identified," said Prof. Oyston. "These could be targets for novel antimicrobial development or could be used in the production of a vaccine."

"Although we are getting closer to addressing key issues such as the need for an effective vaccine, it appears we are still some way from understanding the pathogenesis of F. tularensis. More research is needed in this area."


Contact: Lucy Goodchild
Society for General Microbiology

Related biology news :

1. Stopping unwanted cell death: Implications for drug discovery
2. Steps toward Stopping Autoimmune Disease
3. Tips on how to build a better home for biological parts
4. Genomics of large marine animals showcased in the biological bulletin
5. Securing the future of Europes biological data resources
6. Religion and the narrative of biological science
7. AIBS honors outstanding contributions to the biological sciences
8. Negligent, attentive mouse mothers show biological differences
9. Ancient DNA: reconstruction of the biological history of Aldaieta necropolis
10. U. Iowa study finds biological link between pain and fatigue
11. NYU dental professor discovers biological clock linking tooth growth to other metabolic processes
Post Your Comments:
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... 29, 2015 NXTD ) ... focused on the growing mobile commerce market and ... StackCommerce, a leading marketplace to discover and buy ... smart wallet on StackSocial for this holiday season. ... the "Company"), a biometric authentication company focused on ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... , Nov. 27, 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: ... today that it has closed the sale of its ... Guerbet (GBT- NYSE Euronext) in a transaction valued at ... manufacturing facilities and a total of approximately 1,000 employees ... St. Louis area. This entire ...
(Date:11/26/2015)... England , November 26, 2015 ... medical device company specializing in imaging technologies, announced today that ... Commission as part of the Horizon 2020 European Union Framework ... out a large-scale clinical trial in breast cancer. ... , --> --> ...
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
Breaking Biology Technology: